EUVIMEDEUVIMED entdecken
Crossref

Targeted Macrophage Re‐Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate‐Liposome in RAW264.7 Cells and Arthritic Rats

Simran Nasra, Dhiraj Bhatia, Ashutosh Kumar iD

Advanced Healthcare Materials · 2024

DOI: 10.1002/adhm.202400679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Simran Nasra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biological and Life Sciences, School of Arts & Sciences, Ahmedabad University, Central Campus, Navrangpura, Ahmedabad, Gujarat, 380009, India. Hauptthemen laut MEDLINE: Methotrexate, Folic Acid, RNA, Small Interfering, Macrophages. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Gujarat State Biotechnology Mission, The Gujarat Institute for Chemical Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation and destruction. Current treatments, such as Methotrexate (MTX), though effective, often face limitations such as high plasma C max and lack of sustained release. This study explores a synergistic approach to RA therapy using folate‐liposomal co‐delivery of MTX and RELA siRNA (short interfering RNA), targeting RAW264.7 macrophage repolarization via nuclear factor kappa B (NF‐κB) pathway inhibition. Extensive in vitro characterizations demonstrate the stability and biocompatibility of this therapy via folate‐liposomes. In the collagen‐induced arthritis (CIA) rat model, treatment leads to reduced synovial inflammation and improved mobility. The combined MTX and RELA siRNA approach indirectly inhibits inflammatory cytokines, rheumatoid factor (RF), and C‐reactive protein (CRP). Targeted macrophage delivery shows marked therapeutic effects in RAW264.7 murine macrophages, potentially modulating M1 to M2 polarization. This research presents a promising avenue for innovative RA therapies by inhibiting the inflammatory cascade and preventing joint damage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateFolic AcidRNA, Small InterferingMacrophagesLiposomesTranscription Factor RelAArthritis, RheumatoidAnimalsMiceRAW 264.7 CellsRatsArthritis, ExperimentalMale

Stichwörter der Autor:innen

RELA siRNAfolate liposomeinflammationmethotrexaterheumatoid arthritissynovial macrophages

Substanzen

MethotrexateFolic AcidRNA, Small InterferingLiposomesTranscription Factor RelA

Autor:innen und Institutionen

  • Biological and Life Sciences, School of Arts & Sciences, Ahmedabad University, Central Campus, Navrangpura, Ahmedabad, Gujarat, 380009, India.
  • Biological Engineering Discipline, Indian Institute of Technology, IIT Gandhinagar, Palaj, Gujarat, 382355, India.

ORCID-Profile: Ashutosh Kumar

Förderung

  • Gujarat State Biotechnology Mission
  • The Gujarat Institute for Chemical Technology

Zitieren

APA

Nasra, S., Bhatia, D., & Kumar, A. (2024). Targeted Macrophage Re‐Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate‐Liposome in RAW264.7 Cells and Arthritic Rats. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202400679

Vancouver

Nasra S, Bhatia D, Kumar A. Targeted Macrophage Re‐Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate‐Liposome in RAW264.7 Cells and Arthritic Rats. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202400679

BibTeX
@article{Nasra2024,
  author = {Nasra, Simran and Bhatia, Dhiraj and Kumar, Ashutosh},
  title = {Targeted Macrophage Re‐Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate‐Liposome in RAW264.7 Cells and Arthritic Rats},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  doi = {10.1002/adhm.202400679}
}
Kostenlos starten →